Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. Juni 2026 14:45 ET | Quelle: Crinetics Pharmaceuticals, Inc.

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or...
14. Juni 2026 10:21 ET | Quelle: Celldex Therapeutics, Inc.

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSUSeven months after the completion of dosing (Week 76), up to...
14. Juni 2026 06:30 ET | Quelle: Stemline Therapeutics, Inc.

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination...
13. Juni 2026 09:00 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Agios showcases RISE UP Phase 3 results at EHA 2026 Plenary Session reinforcing strong anti-hemolytic profile of mitapivat in sickle cell disease
13. Juni 2026 08:01 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in...
12. Juni 2026 17:30 ET | Quelle: Traws Pharma, Inc.

Traws Pharma Provides Regulatory Update on Influenza Program

NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral...
12. Juni 2026 16:01 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with...
12. Juni 2026 15:04 ET | Quelle: Crowdability

SpaceX IPO Warning (Crowdability Private Market Profits Newsletter) The Early-Stage Playbook with Exclusive Pre-IPO Research

Paradigm Press Private Market Profits: Matt Milner and Wayne Mulligan monthly investment research newsletter on private-market themes, 2026.
12. Juni 2026 10:00 ET | Quelle: Barrick Mining Corporation

Barrick Publishes 2025 Sustainability Report and Performance Data

TORONTO, June 12, 2026 (GLOBE NEWSWIRE) -- Barrick Mining Corporation (NYSE:B)(TSX:ABX) today published its 2025 Sustainability Report and accompanying performance data, outlining the company’s...
12. Juni 2026 09:00 ET | Quelle: MemeToro AI Labs

AI Memecoin MemeToro Expands Ecosystem as Stage 1 Presale Gains Momentum

ZURICH, June 12, 2026 (GLOBE NEWSWIRE) -- The AI memecoin sector is quickly becoming one of crypto’s fastest-growing narratives. Retail traders are no longer looking only for viral meme coins. Many...

Vorherige Seite

Nächste Seite